Hypocretin/Orexin Regulation of Dopamine Signaling and Cocaine Reinforcement
Hypocretin/Orexin Regulation of Dopamine Signaling and Cocaine Reinforcement
批准号:
10408008
负责人:
Rodrigo A. España
金额:
$37.12万
依托单位:
依托单位国家:
美国
项目类别:
财政年份:
2013
资助国家:
美国
项目状态:
已结题
起止时间:
2013-01-01 至 2024-05-31
关键词:
AbstinenceAcuteAnimalsArousalAttenuatedBehavioralBiochemistryBrainChronic DiseaseCocaineCocaine DependenceCuesDevelopmentDopamineDopamine AgonistsDrug DesignDrug abuseDrug usageHumanHypothalamic structureInjectionsInstitutesLeadMediatingMedicalMotivationMotor ActivityNeuropeptidesNucleus AccumbensPeptidesPeriodicityPharmaceutical PreparationsPharmacologyPharmacotherapyPhasePost-Translational Protein ProcessingProcessPsychological reinforcementPublic HealthRattusRecoveryRegulationReinforcement ScheduleRelapseReportingResearchResistanceRewardsScanningSignal TransductionSystemTechniquesTestingVentral Tegmental AreaWorkabuse liabilityaddictionantagonistawakebasecocaine self-administrationcravingdisorder later incidence preventiondopamine transporterdopaminergic neurondrug abstinencedrug cravingdrug reinforcementgenetic manipulationhypocretinin vivoinsightinterdisciplinary approachmesolimbic systemmotivated behaviorneurochemistryneuromechanismneurotransmissionnovelorexin A receptorpreventpsychostimulantpublic health relevancereceptorrelapse riskrelating to nervous systemresponsestimulant dependence
中文摘要
项目摘要:
精神兴奋剂成瘾是一种慢性疾病,目前还没有批准的药物治疗其
治疗戒毒治疗方面的最大挑战之一是预防吸毒复吸。
在动物中,药物使用后的禁欲期会加剧对药物的渴望和动机,
与复发倾向的增加有关。最近的进展表明,中脑边缘系统的改变
戒断期的多巴胺系统可能是药物渴望加剧的关键组成部分
效果不幸的是,多巴胺为基础的治疗往往是无效的或无法忍受的,并可能有滥用
潜力本身。下丘脑分泌素/食欲素(HCRT)是下丘脑神经肽,参与下丘脑的神经活动。
调节唤醒、运动活动和各种动机行为。在过去的十年里,HCRT
系统也被证明通过多巴胺丰富的腹侧神经元的作用影响药物强化。
被盖区例如,我们已经证明,在腹侧破坏HCRT神经传递,
被盖区减少可卡因的强化作用,并减弱可卡因诱导的
多巴胺在脑桥核内。最近,我们发现了急性HCRT中断的新效应,
导致对可卡因的多巴胺末端敏感性的长期改变,并阻止动机的增加
在戒毒后服用可卡因为了进一步研究HCRT系统调节
多巴胺信号和可卡因强化,拟议的研究将采用多学科的方法,
运用复杂的行为神经化学和基因操控技术研究将检查
急性HCRT受体1阻滞剂对强化行为和多巴胺能神经元损伤的作用
在一段时间的禁欲后对可卡因的反应以及这些作用是否依赖于多巴胺
腹侧被盖区的神经元。这项工作的完成将提供深入了解神经机制
这是成瘾过程的基础,并将为治疗可卡因的新药物疗法提供基础。
成瘾
英文摘要
Project Summary:
Psychostimulant addiction is a chronic disease and currently no approved pharmacotherapies exist for its
treatment. Among the greatest challenges in the treatment of addiction is the prevention of relapse to drug use.
In animals, periods of abstinence following drug use intensifies craving and motivation for drug, which has
been associated with increased propensity for relapse. Recent advances suggest that alterations in mesolimbic
dopamine systems during abstinent periods may be a critical component of the intensification of drug craving
effect. Unfortunately, dopamine-based therapies are often ineffective or intolerable and may have abuse
potential themselves. The hypocretins/orexins (HCRT) are hypothalamic neuropeptides that participate in the
regulation of arousal, locomotor activity, and a variety of motivated behaviors. Over the past decade, the HCRT
system has also been shown to influence drug reinforcement via actions in the dopamine-rich ventral
tegmental area. For example, we have shown that disrupting HCRT neurotransmission within the ventral
tegmental area reduces the reinforcing effects of cocaine and attenuates cocaine-induced elevations in
dopamine within the nucleus accumbens. Recently we discovered a novel effect of acute HCRT disruption that
causes long-lasting alterations in dopamine terminal sensitivity to cocaine and prevents increased motivation
for cocaine following drug abstinence. To further examine the extent to which the HCRT system regulates
dopamine signaling and cocaine reinforcement, the proposed research will employ a multidisciplinary approach
using sophisticated behavioral, neurochemical, and genetic manipulation techniques. Studies will examine the
utility of acute HCRT receptor 1 blockade on the development of intensified behavioral and dopaminergic
responses to cocaine following a period of abstinence and whether these effects are dependent on dopamine
neurons of the ventral tegmental area. Completion of this work will offer insight into the neural mechanisms
underlying the addiction process and will provide the basis for a novel pharmacotherapy to treat cocaine
addiction.
期刊论文(26)
专著(0)
科研奖励(0)
会议论文
登录
查看更多内容
Pharmacologically increasing microtubule acetylation corrects stress-exacerbated effects of organophosphates on neurons.
在药理学上增加的微管乙酰化校正了有机磷酸盐对神经元的应激效果。
DOI:
10.1111/tra.12489
发表时间:
2017-07
期刊:
Traffic (Copenhagen, Denmark)
影响因子:
--
作者:
[Rao AN, Patil A, Brodnik ZD, Qiang L, España RA, Sullivan KA, Black MM, Baas PW]
通讯作者:
Baas PW
DOI:
10.1016/j.brainresbull.2021.07.016
发表时间:
2021-10
期刊:
Brain research bulletin
影响因子:
3.8
作者:
[Gordián-Vélez WJ, Chouhan D, España RA, Chen HI, Burdick JA, Duda JE, Cullen DK]
通讯作者:
Cullen DK
Hypocretin / Orexin Receptor 1 Knockdown in GABA or Dopamine Neurons in the Ventral Tegmental Area Differentially Impact Mesolimbic Dopamine and Motivation for Cocaine.
腹侧被盖区 GABA 或多巴胺神经元中的下丘脑分泌素 / 食欲素受体 1 敲低对中脑边缘多巴胺和可卡因动机产生不同影响。
DOI:
10.1016/j.addicn.2023.100104
发表时间:
2023
期刊:
Addiction neuroscience
影响因子:
--
作者:
[Black,EmilyM, Samels,ShannaB, Xu,Wei, Barson,JessicaR, Bass,CarolineE, Kortagere,Sandhya, España,RodrigoA]
通讯作者:
España,RodrigoA
Selective activation of Dopamine D3 receptors and norepinephrine transporter blockade enhances sustained attention.
选择性激活多巴胺 D3 受体和去甲肾上腺素转运蛋白阻断可增强持续注意力。
DOI:
10.1016/j.neuropharm.2019.01.003
发表时间:
2019
期刊:
Neuropharmacology
影响因子:
4.7
作者:
[Marshall,CourtneyA, Brodnik,ZacharyD, Mortensen,OleV, Reith,MaartenEA, Shumsky,JedS, Waterhouse,BarryD, España,RodrigoA, Kortagere,Sandhya]
通讯作者:
Kortagere,Sandhya
DOI:
10.1002/term.2698
发表时间:
2018-07
期刊:
Journal of tissue engineering and regenerative medicine
影响因子:
3.3
作者:
[Struzyna LA, Browne KD, Brodnik ZD, Burrell JC, Harris JP, Chen HI, Wolf JA, Panzer KV, Lim J, Duda JE, España RA, Cullen DK]
通讯作者:
Cullen DK
共 18 条
Sleep Disturbances During Cocaine Abstinence, Dopamine Adaptations, and Motivation for Cocaine
-
批准号:10681668
-
项目类别:
-
资助金额:$46.92万
-
财政年份:2023
-
负责人:Rodrigo A. España
-
依托单位:
Selective real-time activation of ERK1/2 signaling in dopamine neurons
-
批准号:10706605
-
项目类别:
-
资助金额:$18.94万
-
财政年份:2022
-
负责人:Rodrigo A. España
-
依托单位:
Selective real-time activation of ERK1/2 signaling in dopamine neurons
-
批准号:10539173
-
项目类别:
-
资助金额:$22.73万
-
财政年份:2022
-
负责人:Rodrigo A. España
-
依托单位:
Hypocretin/Orexin Regulation of Dopamine Signaling and Cocaine Reinforcement
-
批准号:9196339
-
项目类别:
-
资助金额:$31.11万
-
财政年份:2013
-
负责人:Rodrigo A. España
-
依托单位:
Hypocretin/Orexin Regulation of Dopamine Signaling and Cocaine Reinforcement
-
批准号:8996680
-
项目类别:
-
资助金额:$34.22万
-
财政年份:2013
-
负责人:Rodrigo A. España
-
依托单位:
Hypocretin/Orexin Regulation of Dopamine Signaling and Cocaine Reinforcement
-
批准号:8788514
-
项目类别:
-
资助金额:$32.33万
-
财政年份:2013
-
负责人:Rodrigo A. España
-
依托单位:
Hypocretin/Orexin Regulation of Dopamine Signaling and Cocaine Reinforcement
-
批准号:8438911
-
项目类别:
-
资助金额:$33.32万
-
财政年份:2013
-
负责人:Rodrigo A. España
-
依托单位:
Hypocretin/Orexin Regulation of Dopamine Signaling and Cocaine Reinforcement
-
批准号:8600248
-
项目类别:
-
资助金额:$32.16万
-
财政年份:2013
-
负责人:Rodrigo A. España
-
依托单位:
Hypocretin/Orexin Modulation of Reward and Addiction Processes
-
批准号:7860686
-
项目类别:
-
资助金额:$14.27万
-
财政年份:2008
-
负责人:Rodrigo A. España
-
依托单位:
Hypocretin/Orexin Modulation of Reward and Addiction Processes
-
批准号:8084181
-
项目类别:
-
资助金额:$2.82万
-
财政年份:2008
-
负责人:Rodrigo A. España
-
依托单位:
Hypocretin/Orexin Modulation of Reward and Addiction Processes
-
批准号:8402255
-
项目类别:
-
资助金额:$13.97万
-
财政年份:2008
-
负责人:Rodrigo A. España
-
依托单位:
Hypocretin/Orexin Modulation of Reward and Addiction Processes
-
批准号:7513648
-
项目类别:
-
资助金额:$13.76万
-
财政年份:2008
-
负责人:Rodrigo A. España
-
依托单位:
Hypocretin/Orexin Modulation of Reward and Addiction Processes
-
批准号:7627941
-
项目类别:
-
资助金额:$14.01万
-
财政年份:2008
-
负责人:Rodrigo A. España
-
依托单位:
Hypocretin/Orexin Modulation of Reward and Addiction Processes
-
批准号:8291423
-
项目类别:
-
资助金额:$18.25万
-
财政年份:2008
-
负责人:Rodrigo A. España
-
依托单位:
海外基金